355 South Grand Avenue, Suite 2450, Los Angeles, CA 90071

California Anesthesia Professionals

Ondansetron Uses and Risks

Ondansetron, also known as Zofran, is primarily used to prevent nausea and vomiting caused by chemotherapy, radiation therapy, and anesthesia [1]. Ondansetron’s mechanism of action involves selectively antagonizing serotonin 5-HT3 receptors located on vagal nerve terminals and in the brain’s chemoreceptor trigger zone [2]. By blocking the action of serotonin in both the central nervous system and the gastrointestinal tract, Ondansetron effectively mitigates symptoms of nausea and vomiting, which are often debilitating for patients [2]. Research has widely supported its efficacy, making it a common choice in multiple clinical settings [1,2,3]. Alongside its many uses, clinicians must also be aware of the risks associated with Ondansetron.

One of the primary uses of Ondansetron is in treating nausea and vomiting during cancer chemotherapy, commonly known as chemotherapy-induced nausea and vomiting (CINV) [3]. It effectively manages both acute and delayed CINV, significantly enhancing the quality of life for patients undergoing treatment. Studies have demonstrated that a single dose of Ondansetron can markedly reduce nausea and vomiting in patients receiving highly emetogenic chemotherapy, allowing them to tolerate their treatment and increasing compliance with chemotherapy regimens [4]. Ondansetron is also effective in managing radiation-induced nausea and vomiting (RINV), particularly in patients receiving radiation therapy to the abdominal or pelvic regions [4]. In both cases, Ondansetron has become a cornerstone of supportive care, alleviating some of the most challenging aspects of cancer therapy [3,4].

While Ondansetron’s clinical uses are well established, it is not without risks [11]. One of the primary concerns associated with its use is its potential to cause QT interval prolongation [11]. This condition can lead to the dangerous arrhythmia known as Torsades de Pointes, which has been documented in some patients [11]. The FDA has issued warnings about this risk, particularly for patients with preexisting heart conditions or those taking other medications that may exacerbate QT prolongation [11]. Given the severity of this side effect, healthcare providers must closely monitor cardiac function in at-risk patients [11].

Additionally, Ondansetron’s association with serotonin syndrome, particularly when used in combination with other serotonergic drugs, adds to the need for careful patient evaluation [10]. Although serotonin syndrome is uncommon, it carries the potential for life-threatening effects and can manifest in any age group [10]. Common symptoms include agitation, cognitive confusion, tachycardia, and elevated blood pressure, and severe cases can result in seizures or fatal outcomes [10]. Healthcare providers should monitor patients for signs of serotonin syndrome when prescribing Ondansetron alongside other serotonergic medications [10].

Another concern is the use of Ondansetron during pregnancy, particularly in the first trimester [8]. Although it is often prescribed off-label for managing nausea and vomiting during pregnancy (NVP), some studies have suggested an increased risk of congenital malformations, particularly cardiac defects, when used during early pregnancy [6,8]. This potential risk has sparked debate within the medical community regarding the safety of Ondansetron in pregnant women [6,8]. Despite these concerns, many clinicians continue to prescribe it for severe cases of NVP, weighing the benefits of symptom relief against the potential risks to the fetus [6,8]. Furthermore, there is limited data regarding the safety of Ondansetron during breastfeeding, complicating decisions in postpartum care [9].

Ondansetron remains an invaluable tool in managing nausea and vomiting, particularly for patients undergoing chemotherapy, radiation therapy, or surgery. Its effectiveness in improving patient outcomes in these settings is well-documented, making it a cornerstone of modern antiemetic therapy. However, alongside its valuable uses, Ondansetron carries significant risks, including cardiovascular complications such as QT prolongation and serotonin syndrome. Additionally, its safety during pregnancy and potential drug interactions must be carefully considered. A thorough assessment of each patient’s medical history and medication regimen is essential to ensure the safe and effective use of Ondansetron. By balancing its therapeutic benefits with its potential risks, healthcare providers can optimize patient care and minimize adverse outcomes.

References

  1. Ashour A. M. (2023). The preventive effects of Ondansetron on chemotherapy-induced nausea and vomiting in adult cancer patients: systematic review from ClinicalTrials.gov. Frontiers in pharmacology, 14, 1310455. https://doi.org/10.3389/fphar.2023.1310455
  2. Ashour A. M. (2023). Efficacy and safety of Ondansetron for morning sickness in pregnancy: a systematic review of clinical trials. Frontiers in pharmacology, 14, 1291235. https://doi.org/10.3389/fphar.2023.1291235
  3. Golshekan, K., Badeli, H., Rezaieian, S., Mohammadpour, H., & Hassanzadehrad, A. (2013). Effect of oral Ondansetron on decreasing the vomiting associated with acute gastroenteritis in Iranian children. Iranian journal of pediatrics, 23(5), 557–563.
  4. Griddine A, Bush JS. Ondansetron. [Updated 2023 Feb 15]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK499839/
  5. Mother To Baby | Fact Sheets [Internet]. Brentwood (TN): Organization of Teratology Information Specialists (OTIS); 1994-. Ondansetron (Zofran®) 2022 Sep. Available from: https://www.ncbi.nlm.nih.gov/books/NBK582886/
  6. Rao, K. V., & Faso, A. (2012). Chemotherapy-induced nausea and vomiting: optimizing prevention and management. American health & drug benefits, 5(4), 232–240.
  7. Simon LV, Torrico TJ, Keenaghan M. Serotonin Syndrome. [Updated 2024 Mar 2]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482377/
  8. Singh, K., Jain, A., Panchal, I., Madan, H., Gupta, A., Sharma, A., Gupta, S., Kostojchin, A., Singh, A., Sandhu, I. S., Mittal, J., Bhogal, L., Kolli, S. T., Bejugam, V. R., Chaturvedi, S., Bhalla, A., & Piplani, S. (2023). Ondansetron-induced QT prolongation among various age groups: a systematic review and meta-analysis. The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology, 75(1), 56. https://doi.org/10.1186/s43044-023-00385-y
  9. Slattery, J., Quinten, C., Candore, G., Pinheiro, L., Flynn, R., Kurz, X., & Nordeng, H. (2022). Ondansetron use in nausea and vomiting during pregnancy: A descriptive analysis of prescription patterns and patient characteristics in UK general practice. British journal of clinical pharmacology, 88(10), 4526–4539. https://doi.org/10.1111/bcp.15370
  10. Theriot J, Wermuth HR, Ashurst JV. Antiemetics, Selective 5-HT3 Antagonists. [Updated 2024 Apr 19]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK513318/
  11. Zhang, W., Shen, Z., Jiang, J. et al. Comparative efficacy of prophylactic protocols in reducing perioperative nausea and vomiting during video-assisted thoracoscopic radical resection of lung cancer. Sci Rep 14, 9818 (2024). https://doi.org/10.1038/s41598-024-59687-z
Share the Post: